Navigation Links
A potential targets for the prevention or treatment of esophageal carcinoma
Date:10/29/2008

Expression of Livin in fresh esophageal cancer tissues was detected by immunohistochemistry (IHC), Western blotting and reverse transcriptase-polymerase chain reaction (RT-PCR), VEGF by Its correlation Western blotting and RT-PCR. Livin positivity was also significantly correlated with tumor stages, increasing with tumor progression. Expression of Livin and VEGF increased with the process of esophageal carcinoma. In the fourth clinical stage, expression of Livin and VEGF was the most significant. Expression of Livin was positive correlation with VEGF. Over-expression of Livin and VEGF contributes to the pathogenesis of esophageal carcinoma.

A research article to be published on October 7, 2008 in the World Journal of Gastroenterology addresses this question. The research team led by Professor

Ren GS Cancer Institute of Chiongqing Medical University used molecular biology technology to investigate the role of Livin and VEGF in human esophageal carcinoma and analyze its relationship with clinical stages.

In the present study, authors investigated expression of Livin in human esophageal carcinoma and analyze its relationship with clinical stages. The results showed that Livin positivity was also significantly correlated with tumor stages, increasing with tumor progression. Expression of Livin increased with the process of esophageal carcinoma. In the fourth clinical stage, expression of Livin was the most significant. The results showed that VEGF positivity was also significantly correlated with tumor stages, increasing with tumor progression. Expression of VEGF increased with the process of esophageal carcinoma. In the fourth clinical stage, expression of VEGF was the most significant.

Taken together, over-expression of Livin and VEGF contributes to the pathogenesis of esophageal carcinoma. Level of VEGF has positive correlation with Livin. The hypothesis has been made that Livin and VEGF played such an inter-enhancement role in the progress of esophageal carcinoma. Inhibitors of Livin and VEGF may be potential targets for the prevention or treatment of human esophageal carcinoma.


'/>"/>

Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. ETHEX Corporation Voluntarily Recalls Three Lots of Dextroamphetamine Sulfate 5mg Tablets Due to the Potential for Oversized Tablets
2. Potential treatment option for severe emphysema under study
3. How to Help Down Syndrome and Other Special Needs Children - Free Booklet and Parenting Course Available This Month From The Institutes for the Achievement of Human Potential
4. Vasculitis Foundation Integrates Education, Outreach and Technology in First-Ever Webinar on Potentially Life-Threatening Disease
5. A potential approach to treatment of hepatitis B virus infection
6. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
7. Measures to assess potential lung injury during ventilation inadequate
8. Malaria prevention reduces anemia and improves educational potential in Kenyan schoolchildren
9. PMC and County Announce Potential Capital Partners for Hospital
10. Announcement Outlines 36 Month Custom Deployment Contract With Potential Revenues Reaching $30 Million Dollars
11. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one ... video series titled The Thyroid Secret. Dr. Wentz talked about journey and research recently ... fact that medication IS NOT the only solution to deal with thyroid disease. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... and by physicians, announced today the launch of a free, public-facing tool for ... Cost Analyzer (VCA) was developed to provide comparative information to patients, providers, insurers ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm , the ... headquarters to a new, more expansive office space in order to accommodate its ... a distressed office building in Wethersfield, Conn. located at 936 Silas Deane Highway ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... REDWOOD CITY, Calif. , March 28, 2017 ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that the European Medicines Agency ... (sufentanil sublingual tablet, 30 mcg) Marketing Authorisation Application ... review of the MAA is underway. The MAA ...
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
(Date:3/27/2017)... 2017 Therapix Biosciences Ltd. ... in the development of cannabinoid-based drugs, today announced ... the United States of 2,000,000 ... ordinary shares of the Company, at a price ... granted the underwriters a 45-day over-allotment option to ...
Breaking Medicine Technology: